Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.62 |
| ▸ | PLG | P00747 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890728 | 1.00 | MAP3K5 (0.62) | MAP3K5PLGMAPTAPEX1PTPN22 | |
| SCHEMBL3890731 | 1.00 | MAP3K5 (0.62) | MAP3K5PLGMAPTAPEX1PTPN22 | |
| SCHEMBL14860504 | 0.93 | MAP3K5 (0.62) | MAP3K5PLGMAPTAPEX1PTPN22 | |
| SCHEMBL23433479 | 0.93 | MAP3K5 (0.62) | MAP3K5PLGMAPTAPEX1PTPN22 | |
| SCHEMBL14860506 | 0.93 | MAP3K5 (0.62) | MAP3K5PLGMAPTAPEX1PTPN22 | |
| SCHEMBL3896520 | 0.87 | POLB (0.57) | MAP3K5MAPTPTPN22MEN1POLB | |
| SCHEMBL3896523 | 0.87 | POLB (0.57) | MAP3K5MAPTPTPN22MEN1POLB | |
| SCHEMBL3904803 | 0.85 | MAP3K5 (0.82) | MAP3K5MAPTAPEX1PTPN22 | |
| SCHEMBL3904806 | 0.85 | MAP3K5 (0.82) | MAP3K5MAPTAPEX1PTPN22 | |
| SCHEMBL3893802 | 0.84 | ALDH1A1 (0.56) | MAP3K5MAPTPTPN22MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | MAP3K5 2933/4885PLG 479/4885MAPT 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.